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in the EPO group was matched by Hb and GFR to one control
CKD patient not receiving EPO. The time from when the EPO
and matched control patients had the same GFR value to dialy-
sis was compared. The economic impact of EPO on delaying
dialysis was monetized using published Medicare expenditures
in 2001, adjusted to 2005, at $1204 per member per month
(PMPM) prior to end-stage renal disease (ESRD) and $6020
PMPM for the post-ESRD period, and was calculated as the
PMPM cost difference between the post- and pre-ESRD periods
multiplied by the number of months of delay to dialysis by EPO.
RESULTS: Sixty-eight patients (34 EPO and 34 controls) formed
the study population. Mean age was similar between the two
groups (years; EPO: 75.0 vs. control: 75.3), with a higher pro-
portion of men in the EPO group (68% vs. 44%). The average
time to dialysis was 156 days longer for the EPO group (319 ±
252 vs. 163 ± 151 days, P = 0.003), resulting in cost savings of
$25,044 per patient relative to the control group. CONCLU-
SIONS: This matched cohort analysis suggested that elderly
CKD patients receiving EPO had a longer time to dialysis, thus
reducing medical costs. These ﬁndings need to be further 
validated.
UR2
ECONOMIC BURDEN OF UNTREATED ANEMIA IN PRE-
DIALYSIS CHRONIC KIDNEY DISEASE (PCKD) PATIENTS: AN
EMPLOYER’S PERSPECTIVE
Moyneur É1, Bookhart B2, Mody S2, Fournier AA1, Mallet D3,
Duh M4
1Groupe d’Analyse, Inc, Montréal, QC, Canada, 2Ortho Biotech
Clinical Affairs, LLC, Bridgewater, NJ, USA, 3Ingenix Employer
Solutions, New Haven, CT, USA, 4Analysis Group, Inc, Boston, MA,
USA
OBJECTIVE: Patients with CKD typically have progressive loss
of kidney function, eventually leading to anemia. Anemia of
pCKD may contribute to worsening of health, resulting in higher
costs to employers. This analysis quantiﬁes the economic burden
of untreated anemia in pCKD patients from an employer’s per-
spective. METHODS: A retrospective analysis was conducted
using anonymous health and disability claims from 31 U.S.
employers between January 1998 and January 2005 from
approximately 5 million individuals. A total of 7258 pCKD
patients with at least two CKD claims less than 90 days apart
prior to dialysis, not receiving anemia therapy with erythropoi-
etic-stimulating agents and with no history of organ transplant
were identiﬁed. Of these, 1534 (21%) with at least 2 anemia
ICD-9 diagnosis claims were classiﬁed as anemic. The anemia
period was from the ﬁrst anemia claim to disenrollment, organ
transplant, or study end. The remaining 5724 patients provided
the non-anemia reference period. To isolate costs speciﬁc to
anemia, multivariate regression analyses were conducted to
control for liver cirrhosis, hypertension, chemotherapy, Charlson
Comorbidity Index, age, sex, health plan, and region. Employ-
ers’ costs comprised direct medical/indirect productivity (short-
and long-term disability, sick leave). RESULTS: Univariate and
multivariate analyses indicated that untreated anemia was asso-
ciated with statistically signiﬁcant increases in direct and indirect
costs. The univariate incremental monthly direct and indirect
costs of untreated anemia were $1344 ($2401 untreated anemic
vs. $1057 non-anemic, p < 0.001), a 2.3 :1 cost ratio, and $271
($620 vs. $349, p < 0.001), a 1.8 :1 cost ratio. Multivariate
analyses conﬁrmed that incremental monthly direct and indirect
costs for untreated anemia remained signiﬁcant at $855 (p <
0.001), a 1.8 :1 cost ratio, and $164 (p < 0.001), a 1.5 :1 cost
ratio. CONCLUSIONS: Untreated anemia in pCKD patients was
associated with signiﬁcantly higher direct and indirect costs to
employers. Studies are needed to evaluate cost-effectiveness of
treating anemia of pCKD.
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OBJECTIVE: To identify factors associated with the decision to
seek care from a health professional for overactive bladder
(OAB) symptoms. METHODS: A cross-sectional survey was
conducted to identify US adults with symptoms of OAB. The
sampling frame was selected from an existing consumer panel of
600,000 households. A 2-stage sampling scheme was used to
obtain the target subsample (n = 260,000) of individuals repre-
sentative of US adults for age, sex, geographic area, household
size, and urban versus rural location. The survey used the Over-
active Bladder-Validated 8 (OAB-V8) instrument (total score
ranging from 0–40) and additional questions probing health
care-seeking behavior and treatment patterns. Only subjects
scoring ≥8 (ie, probable OAB) on the OAB-V8 were included in
this analysis. Classiﬁcation and regression tree analysis was used
to identify the demographic characteristics and symptoms asso-
ciated with consulting a health care professional (ie, physician
or nurse). RESULTS: Of the 162,906 subjects returning the
survey (63% response rate), 43,252 (27%) had a score ≥8. Of
these, 19,761 (46%) reported that they had consulted a health
professional regarding their bladder symptoms. Sex, “urine loss
associated with a strong desire to urinate” (UL) and “frequent
urination-daytime hours” (frequency) were most strongly asso-
ciated with consulting. The full tree model, which consisted of 9
variables and 2835 nodes, produced a misclassiﬁcation rate of
29%. A limited tree with only sex, UL, frequency, and 6 nodes
produced a 39% misclassiﬁcation rate. CONCLUSIONS: A
number of characteristics inﬂuenced the decision to seek health-
care for bladder symptoms, with the 3 strongest characteristics
being: 1). female gender; 2). a bother rating of “a little bit” or
more from UL; and 3). a bother rating of “some” or more from
frequency. Additional research is needed to identify other factors
that contribute to healthcare-seeking behaviors.
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OBJECTIVES: Approximately 30% of women of reproductive
age complain of abnormal uterine bleeding (AUB). The objec-
tives of this study were to compare the cost-effectiveness of treat-
ment strategies with the levonorgestrel-releasing intrauterine
system (LNG-IUS), combined oral contraception pills (OCs), or
surgical treatment (endometrial ablation or hysterectomy) for
managing AUB in women who do not desire more children.
METHODS: A Markov model was constructed from the per-
spective of payers over a 5-year period with a 1-year cycle length.
Model inputs were obtained from a comprehensive literature
review. Treatment costs included: drug, device, hospitalization,
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procedure, physician visits, and contraceptive method failures.
Effectiveness was deﬁned as both control of uterine bleed and
contraception success. We studied three clinical scenarios: sce-
nario 1 compared LNG-IUS with OC in women who responded
to initial trials of OCs; scenario 2 compared surgery with LNG-
IUS among women who did not respond to an initial trial of
OCs; and scenario 3 compared LNG-IUS and OC for women
who are naïve to medical therapy. In all scenarios, surgery fol-
lowed if medical therapy failed. RESULTS: In scenario 1, LNG-
IUS was both more effective (92% vs. 90.4%) and less expensive
($2796 vs. $4711) than OC. In scenario 2, surgical management
was slightly more effective than LNG-IUS (95.5% vs. 92.0%
success rate) but at a much higher cost ($4m853 vs. $2,796 per
woman), and was associated with an additional cost of approx-
imately $60,000 per additional successfully treated woman. In
scenario 3, LNG-IUS achieved similar outcomes compared to
OCs (92% vs. 93.6%) but at a much lower cost ($2796 vs.
$4895). The results of the model were robust over changes of
assumptions and variations of key variables. CONCLUSIONS:
The treatment strategy with LNG-IUS was the most cost-
effective approach to managing AUB, regardless of whether or
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OBJECTIVES: Published data on costs associated with treating
privately insured patients with hepatocellular carcinoma (HCC)
or metastatic liver disease (MLD) are limited. This study evalu-
ated health resource use and medical care costs in newly diag-
nosed HCC and MLD patients. METHODS: Patients diagnosed
with HCC or MLD in 2002 were identiﬁed from a nationally
representative private payer claims database by ICD-9 diagnosis
codes, using the date of the ﬁrst diagnosis as the “index date”.
Patients were required to be 18 years of age or older, with no
prior HCC or MLD diagnosis, and continuously enrolled in a
health plan. Health resource use and medical care costs were
tracked over one year. RESULTS: The study included 297 HCC
and 846 MLD patients. The mean age for all patients was 56.8
years and 41% were male. MLD patients had signiﬁcantly higher
inpatient admissions versus HCC patients (2.1 vs. 1.5, p <
0.001), while the mean aggregate hospital days was signiﬁcantly
longer in HCC patients (16.5 vs. 14.2, p < 0.001). MLD patients
also had signiﬁcantly greater emergency room, outpatient hos-
pital, and physician ofﬁce visits (p < 0.05). Total mean medical
costs were signiﬁcantly higher in MLD patients ($93,786) versus
HCC patients ($37,203, p < 0.001). These higher costs were due
primarily to signiﬁcantly greater ancillary costs in MLD patients
($54,671 vs. $5,903, p < 0.001), which include costs associated
with chemotherapy. All differences remained signiﬁcant after
adjusting for differences in age and sex. CONCLUSIONS:
Among managed care patients newly diagnosed with HCC or
MLD, signiﬁcantly higher 1-year health resource use and medical
care costs were found for MLD patients. The difference in overall
costs was due primarily to the higher use of ancillary services
among MLD patients. These ﬁndings provide important new
data for evaluating the economic impact of treating HCC and
MLD patients.
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OBJECTIVES: Estimate national trends in mammography
screening use among elderly Medicare beneﬁciaries for the period
of 1998 to 2001; determine the extent to which socio-
demographic, clinical, and access factors are associated with 
disparities in screening use. METHODS: A secondary data
analysis of the Medicare Current Beneﬁciary Survey (MCBS) was
conducted. Community-dwelling women aged >65 years who
completed the MCBS at least once during the survey years of
1998 to 2001 were included. Having had a mammogram in the
past year was determined by a participant’s response to the ques-
tion “have you had a mammogram or a breast x-ray since a year
ago?”, or by a Medicare claim coded with a mammogram pro-
cedure in the calendar year. Multivariate logistic regression was
used to estimate the association between the likelihood of having
had mammogram in the past year and factors, such as socio-
demographic, biological, and access factors. Sampling weights
were used to reﬂect national estimates of Medicare beneﬁciaries.
Standard errors were adjusted for clustering and stratiﬁcation in
the complex sampling design. RESULTS: A total of 10,757
females 65 years of age or older responded to the MCBS from
1998 to 2001 (weighted N = 34 million). Over half (54%, 95%
CI 53%–55%) of the respondents had mammogram in the past
year. Annual mammography screening rates increased over time,
from 49% in 1998 to 58% in 2001. In adjusted models, there
was no signiﬁcant racial or ethnic disparity in mammography
use, but the other socio-demographic factors remained signiﬁ-
cantly associated with lower odds of mammography use. CON-
CLUSIONS: Mammography screening rates increased notably
between 1998 and 2001 in the Medicare population. While no
racial or ethnic disparities in screening rates were noted in this
study, lower income, less education, no insurance and being
unmarried were identiﬁed as barriers to breast cancer screening
for elderly Medicare beneﬁciaries.
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OBJECTIVE: In the late 1990’s, a U.S. health policy initiative
recommended that colorectal cancer screening begin at age 50
for all adults. Shortly thereafter, Medicare began paying for
screening colonoscopy in average risk persons. In the years that
followed, the mix of procedures performed to evaluate colon
health in Medicare beneﬁciaries changed; colonoscopy proce-
dures increased and other colorectal cancer screening procedures
decreased. We conducted this study to evaluate trends in col-
orectal cancer screening procedure volumes in private-pay
patients between 2000 and 2004. METHODS: A nationally rep-
resentative private payer claims database was used to identify
patient records with claims for colonoscopy, ﬂexible sigmoi-
doscopy, double-contrast barium enema, and fecal occult blood
test (FOBT) during 2000–2004. CPT and HCPCS procedure
codes were used to identify patient records with claims for the
procedures of interest. Only patients aged 18+ were included in
the analysis. RESULTS: Patients in the study sample averaged 53
years of age and were 60% female. From 2000 to 2004 the pro-
portion of screening procedures performed relative to the
number of plan members increased 38% (8% to 11%). Relative
